KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024.

Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State Health, and KONFIDENT investigator, presented data on theCorrelation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trialthat showed complete attack resolution was achieved faster in attacks that were treated earlier (1st quartile) compared with those treated later (4th quartile).

"This is the first time in a Phase...